Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen.
OBJECTIVE
We previously reported that 0.625 mg/day of conjugated equine estrogen (CEE) could not prevent acute bone loss in the first year after oophorectomy. The effect of additional administration of ipriflavone on bone mineral density (BMD) and biochemical indices of bone remodeling were studied to investigate whether concurrent use of CEE and ipriflavone prevent acute bone loss in the early stages following surgical menopause.


METHODS
One-hundred and sixteen oophorectomized women were randomly divided into four groups according to treatment; group 1: placebo, n = 30; group 2: CEE (0.625 mg/day), n = 29; group 3: ipriflavone (600 mg/day), n = 30; group 4: CEE (0.625 mg/day) plus ipriflavone (600 mg/day), n = 27. Vertebral BMD was measured using dual energy X-ray absorptiometry (DEXA) and two biochemical indices of bone metabolism, urinary pyridinoline (Pyr) and serum intact human osteocalcin (hOC), were also measured before, 24 weeks, and 48 weeks after initiation of treatment.


RESULTS
BMD was reduced 48 weeks after treatment by 6.1, 3.9 and 5.1% in groups 1-3, respectively, but by only 1.2% in group 4. Pyr decreased by 49.5, 32.0 and 41.5% in groups 2-4, respectively. hOC also decreased by 45.2 and 21.6% in groups 2 and 4, but increased by 40.5% in group 3, suggesting an inhibitory action of CEE and ipriflavone on the turnover of bone metabolism and stimulatory action of ipriflavone on bone formation.


CONCLUSIONS
Concomitant use of ipriflavone with CEE from an early stage after oophorectomy inhibited bone loss and was considered to be effective in maintaining bone mass after oophorectomy.
Nozaki
M
M
Department of Gynecology and Obstetrics, Kyushu University, Fukuoka, Japan.
Hashimoto
K
K
Inoue
Y
Y
Ogata
R
R
Okuma
A
A
Nakano
H
H
D015502:Absorptiometry, Photon; D000328:Adult; D000596:Amino Acids / Q000652:urine; D000700:Analgesics; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects; D004359:Drug Therapy, Combination; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use*; D008875:Middle Aged; D015675:Osteocalcin / Q000652:urine; D010024:Osteoporosis / Q000517:prevention & control*; D010052:Ovariectomy
D000596:Amino Acids; D000700:Analgesics; D004966:Estrogens, Conjugated (USP); D007529:Isoflavones; D015675:Osteocalcin; C015484:pyridinoline; C018986:ipriflavone